

Optimization of Ibuprofen Carrying Poly-(3-Hydroxybutyrate) Extended Release Tablet by Central Composite Design

Akshay Jirage¹, Khyyam Shaikh¹, Kate Vaishali¹, Payghan Santosh^{1,2*}

¹Department of Pharmaceutics, Tatyasaheb Kore College of Pharmacy, Warananagar, Tal. Panhala, Dist. Kolhapur-416113, India

²Shivaji University, Kolhapur, India

Abstract

Context: Novel poly-(3-hydroxybutyrate)-based systems for controlled release of anti-inflammatory drug has been studied.

Methods: Ibuprofen diffusion processes determine the rate of the release at the early stages of the contact of the system with the environment (the first 6-8 h). The coefficient of the release diffusion of a drug depends on its nature, the thickness of the poly-(3-hydroxybutyrate) films containing the drug, the concentrations of Ibuprofen, and the molecular weight of the poly-(3-hydroxybutyrate). The use of central composite design (CCD) is used to map the optimal composition range for process parameters; this technique is mainly used to map the optimum ER Tablets. PHB base ER tablet of ibuprofen was prepared by direct compression technique and characterized by physicochemical parameters. The prepared tablets were evaluated physical properties hardness, friability, disintegration time and *in vitro* drug release.

Results and discussion: The drug release pattern, kinetic profiles as well as the low rate of IF release from the tablet is in satisfactory agreement with kinetics of weight loss measured *in vitro* for the PHB Tablet.

Conclusion: The results obtained are critical for developing systems of release of diverse drug, thus, enabling the attainment of the requisite physiological effects on tissues and organs of humans.

Keywords: Poly-β-hydroxybutyrate (PHB) biodegradable polymers, Extended Drug Release, Central composite design.

Accepted November 23, 2016

Introduction

Bio-based polymers are materials which are produced from renewable resources [1]. The terms bio-based polymers and biodegradable polymers are used comprehensively in the literature, but there is a key difference between the two types of polymers [2]. Biodegradable polymers are defined as materials whose physical and chemical properties undergo decline and completely mortify when exposed to microbes, carbon dioxide (aerobic) processes, methane (anaerobic processes), and water (aerobic and anaerobic processes) [3-4]. Bio-based polymers can be biodegradable or non-degradable. Similarly, while many bio-based polymers are biodegradable, not all biodegradable polymers are bio-based [5]. Biodegradable polymers are seen as the budding solution to manage problems concerning worldwide environmental and solid waste management. These biodegradable plastic materials can retain the desired material properties of conformist synthetic plastics, and can be completely degraded without parting any undesirable rest [6]. With the aim of substituting the functionality of

plastics of petrochemical source, as well as mounting the range of application of bioplastics to an extensive range, polyhydroxyalkanoates (PHAs) are supposed as the most suitable materials because of their adaptability in terms of physical properties and chemical characteristics [7].

Accumulation of polyhydroxyalkanoates (PHAs) in bacteria, a natural biodegradable and biocompatible thermoplastic polymer, has been well documented throughout the years since its discovery in 1925 by Lemoigne [8]. The polymer composition largely depends on the type of bacteria as well as the carbon sources used in the fermentation process. Thus, the PHA family represents an interesting group of biodegradable polymers that can be produced from renewable resources and have various applications, e.g., in packaging, agriculture, marine, and medical fields. Among the 150 different types of PHA produced in bacteria, homopolymer P-(3HB) is the most studied PHA up to now [8].

Polyhydroxybutyrate (PHB) is the most widely studied

member of the PHA family and the first one that has been produced at industrialized scale. It has been used, among other applications, to produce bottles, films, and fibers for biodegradable wrapping materials and as mulch films for agriculture [9,10]. However, applications of PHB are not restricted to these areas, and they have been extensive to osteosynthetic resources, bone plates, surgical sutures, rivets, tacks, and many other materials in medicine [9,11]. At industrial level, PHB is commonly produced from *Cupriavidus necator* (*Alcaligenes eutrophus*) and *Alcaligenes latus* (*Azohydromonas lata*). These microbes can accrue PHB up to 80% of the dry cell weight [12].

There is generous interest in development of biodegradable polymer like PHB by environmentally efficient bacterial origin. This may help to solving trouble produced by synthetic or semi-synthetic polymer. Synthetic Polymer may produce hazardous problem during formulation that produce the bioaccumulation in the body [13]. This accumulated trace of polymer creates health related problems. PHB are found functionally more and can be better for use in pharmaceutical formulations. This will help to improve pharmaceutical drug delivery of different therapeutic agent [13]. This biopolymer is effective tool to control or extend the drug release rate of pharmaceutical formulation. PHB is the biopolymer include in formulation because of their thermoplasticity and biodegradability features [12]. It is considered as more environmentally friendly and sustainable method for obtaining the polymer. These improvements contribute to make medical treatment more efficient and to minimize side effects and other type inconvenience for patients [13,14].

The current study was based on screening of biopolymer which would satisfy the rising demand of sustainable economic biopolymer production from bacterial genera. Screened Poly- β -hydroxybutyrate (PHB) has found to be an optimistic role in biomedical applications and pharmaceutical drug delivery scenario. The variety of (semi) synthetic polymer available in market and these many synthetic polymers are being used now-a-days in drug delivery systems synthetic polymers have certain disadvantages such as their high production cost, non-biodegradability, toxicity, and so it proven their impact on probability of bioaccumulation [15]. Such accumulation for long time hampers the human health. Hence these demerits avoided by application of screened biopolymer candidate PHB as drug release retardant tool [15].

The buildup of inflammatory processes may be regulated by systemic administration of anti-inflammatory preparations [14]. In certain cases, however, this approach is not efficient, because the local concentrations of the drugs within the region of the implantation are either not sufficient for attaining the pharmacological effect or lack stability, whereas any further increase in the dose administered systemically entails side effects [14]. Systems of controlled release of drugs, based on polymer materials, make it possible to regulate the processes of

inflammation, thrombus formation, and development of new tissue within the immediate vicinity of implantation of medical devices. In designing such systems, it is important to make the right choice of the drug [14].

The use of Central Composite experimental design (CCD) is required to map the optimal composition range for process parameters; this technique is mainly used to map the optimum nano emulsion, Tablets, suspensions etc. [16,17]. In the present work, the preparation of Ibuprofen loaded PHB based ER Tablet is discussed and use of CCD explored to map the optimal composition range and can be used to show the influence of composition of PHB on extended release pattern ibuprofen.

Ibuprofen (IF), a nonsteroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase, thereby preventing the synthesis of prostaglandins (which are major mediators of inflammation), and cell proliferation [14]. It is noteworthy that IF, as well as PHB, are soluble in organic solvents (chloroform and methylene chloride), which simplifies the technology of creating polymer systems of controlled release [10].

The molecular weight (MW) of a polymer considerably affects the kinetics of the release of drugs introduced into its matrix [13]; for this reason, development of controlled release systems for drug that have predefined characteristics requires a technology for synthesizing polymers with a particular MW. When PHB is obtained using biotechnological methods, the conditions of culturing of the PHB producer strains may influence the molecular weight of the polymer [13]. Thus, a technology for the biosynthesis of PHB with a defined MW is prerequisite to creating controlled release systems for the requisite characteristics of the kinetics of the drug release from the polymer matrix. The use of such systems for controlled release of anti-inflammatory drugs is expected to regulate inflammatory processes and the rate of the implant biodegradation and capsulation. In this work, we sought to obtain and study PHB based films incorporating IF.

Materials and Methods

Reagents and samples

All the Analytical grade materials were used. Ibuprofen reference standard was collected from Asoj Soft Caps. Pvt. Ltd., India. Extended release tablets were formulated using mannitol, talc, Mg stearate, colloidal silicon dioxide (Aerosil) as excipients. Acetonitrile (HPLC grade), Distilled water (HPLC grade) were used as analytical grade solvent for analysis purpose [18]. All the excipients and solvents were purchased from Loba Cheme, Mumbai. The reagents 0.1 N Sodium Hydroxide, Phosphate buffer solution pH 7.2, PBS (pH 6.8) was prepared according to compendial procedure [19].

Analytical method

All the chemicals and reagents were made according to

official compendial requirements. The 0.2 N sodium hydroxide (NaOH), N Hydrochloric Acid (HCL), 0.2 M Potassium chloride (KCl), 0.2 M Potassium dihydrogen phosphate (KH_2PO_4), Hydrochloric acid Buffer solution pH 1.2, Phosphate buffer solution pH 6.8 etc. were prepared according to compendial specifications.

Biosynthesis of PHB

The PHB strain used in this work (*Bacillus megaterium* ATCC 6748) was capable of synthesizing PHB in an amount of up to 80% on the dry weight basis of the cells [20-22]. A lyophilized culture was reactivated at 30°C for 24 h in a growth medium as Nutrient agar medium containing Nutrient Agar (NA) 3.5%, Peptone 2.5%, NaCl 0.5%, Yeast 0.1%, Beef extract 0.5%, Agar powder 3% and Distilled water [23]. The nutrient components as sugar, nitrogen, phosphate and trace elements were sterilized separately at 121°C for 20 min. A collection of strains of the genus *Bacillus megaterium* were maintained on Nutrient Agar medium [23]. To achieve cellular PHB hyper production, the culture of the *Bacillus megaterium* strain was grown on nutrient agar medium in excess of content of the carbon source [24]. The process of isolation and purification from the biomass of *Bacillus megaterium* ATCC 6748 included the following stages: dissolution of PHB in chloroform by shaking at 37°C for 12 h, separation of the PHB solution from the cell residue by filtration, isolation of the PHB by non-solvent precipitation method comprising (7:3 v/v) methanol and water, and repeated its dissolution in chloroform followed by saturated cell mass suspension precipitation and drying at 60°C PHB crystals emerge out [19-24].

Drug interactions with PHB

All Interactions between the ibuprofen and PHB base polymer were studied by spectral and thermodynamic changes for evaluation of physical and chemical integrity of prepared ER tablets.

Infra-red spectral analysis: The Possibility of drug excipient interaction was investigated by Fourier Transform Infra-red spectroscopy (Cary-60 ATR, Agilent). The FTIR spectra of ibuprofen and drug PHB mixtures were recorded. FTIR spectrometer in the range of 4000-400 cm^{-1} , study was carried out to detect any changes on chemical constitution of the drug after combined it with the PHB [25,26].

Differential Scanning calorimetry: Thermo grams of pure ibuprofen were taken for DSC study. An empty aluminum pan was used as a reference. DSC (METTLER TOLEDO STARE System, Germany) measurements were performed at a heating rate of 5°C/min from 50-400°C using aluminium sealed pan. The sample size was 5 mg of ibuprofen and 5 mg of physical mixture of PHB for measurements. During the measurement, the sample cell was purged with nitrogen gas at 40 ml/min [27-29].

PHB based extended release Ibuprofen tablet

Preparation of mixtures/powder blend: Coarse (lactose monohydrate) and polymer (PHB/HPMC K100 M) were covered with Ibuprofen by dry mixing. This material was mixed in a teflonized metal jar of All Purpose Mixer (Shakti corp., Mumbai) at 90 rpm for 24 hrs. Talc, Mg stearate, colloidal silicon dioxide (Aerosil) were added to the interactive mixture and mixed at 30 rpm for an additional 48 hrs. The flavor was added in interactive mixture and mixed for 1 hr at 30 rpm [30,31].

Determination of mixture homogeneity: The content of Ibuprofen was used to express the quality (i.e. heterogeneity) of the mixtures. Samples of each mixture weighing 500 mg were withdrawn with the aid of sample thieves/Spatula [32]. The amount of Ibuprofen in the samples was measured spectrophotometrically (Shimadzu corp. Japan) at a wavelength of 222 nm.

Compaction of tablets: Prior to compaction, all tablet masses were mixed with magnesium stearate in the tumbling mixer at 30 rpm for 2 min. Tablets were made in 8 station Rota press (Karnavati, Ahmadabad) using 9 mm flat edged punches; the powder was filled into the die with a feed frame. The tablets contained Ibuprofen 200 mg in bases. Each batch comprised 100 tablets. Ibuprofen extended release tablets were prepared by direct compression method [33,34]. A total number of thirteen formulations (F1 to F13) of Ibuprofen tablets were prepared.

Before tablet preparation, the mixture blend of the formulations were subjected to precompression study parameters like Angle of repose, bulk density, tapped density, compressibility index and hausner's ratio [35,36].

Design of experiment

Optimization PHB based extended release Ibuprofen tablet: In this work, central composite design (CCD) was used simultaneously to study the effect of the two process parameters involved in the preparation of ER tablet by direct compression against two response variables. CCD is a response surface design which provides information on direct effects, pair-wise interaction effects, and curvilinear variable effects and is widely used for formulation and process optimization in the field of pharmaceuticals [37].

The main object of the present study to use optimum quantity of polymer in formulation with application of variable compression force to obtain the effective ER compact with hardness that would provide mechanical strength to the formulation [38]. The obtained ER tablet withstand the drug release for prolonged period time, central composite design (CCD) was selected with 2 factor, 3 level and 13 run was selected to statistically optimize the formulation parameter and evaluate the main effects, interaction effect and quadratic effect of the formulation ingredient on the hardness, % drug release of Ibuprofen ER tablet. 3- factor 2- level design was used in the study to

explore quadratic response surfaces and for constructing polynomial models thus helping in optimizing a process formula using a small number of experimental runs [39].

The polynomial equation generated by this experimental design using Reliasoft® DoE++ V.9.0.6 generated polynomial models including interaction and quadratic terms were generated for all the response variables using multiple linear regression analysis (MLRA) approach [39].

$$Y = \beta_0 + \beta_1 X_1 + \beta_2 X_2 + \beta_3 X_1 X_2 + \beta_4 X_1^2 + \beta_5 X_2^2 + \beta_6 X_1 X_2^2 + \beta_7 X_1^2 X_2$$

Where,

β_0 is the intercept representing the arithmetic average of all quantitative outcomes of 13 runs;

β_1 to β_7 are the coefficients computed from the observed experimental values of Y; and

X_1 and X_2 are the coded levels of the independent variable(s).

The terms $X_1 X_2$ and X_i^2 ($i=1$ to 2) represent the interaction and quadratic terms, respectively [22]. Statistical validation of the polynomial equation was established on the basis of ANOVA provision in the Reliasoft® DoE++ V.9.0.6 Software. Various feasibility and grid searches were conducted to find the composition of optimum formulations. Also, the 3-D response surface graphs and 2-D contour plots were constructed using the graphical output files generator.

Independent variable studied were the polymer concentration (mg) (X_1), Compression Force (Tons) (X_2). The dependent variable were hardness (Kg/cm²) (Y_1) and cumulative drug release (%) (Y_2). The concentration range of independent variable along with their low, medium and high levels, were selected based on the results from preliminary experiments.

Optimization data analysis: The response surface methodology is a collection of mathematical and statistical techniques used for modeling and analysis of problems in which a response of interest is influenced by several variable and the objectives is to optimize this response. The run or formulation, which are designed based on central composite design are evaluated for the response. The response values are subjected to multiple regressions analysis to find out the relationship between the factor used and the response value obtained [40]. The computation for optimized for optimized formulation was carried using software Reliasoft® DoE++ V.9.0.6 office. The optimized formulation was obtained by applying constraints on dependent (Response) and independent variables (Factors). The models were evaluated in terms of statistically significant coefficient and R² values. Various feasibility and grid searches were conducted to find optimum parameters. Various 3-D response surface graphs were obtained from Reliasoft® DoE++ V.9.0.6 software.

Statistical analysis: Statistical analysis of Central composite design was performed by multiple regression analysis using Microsoft Excel. To analyze the contribution of each factor with different level to response, the two way analysis of variance (ANOVA) was performed using the Reliasoft® DoE++ V.9.0.6 software. To graphically demonstrate the influence of each factor on the response, the response surface plots were generated using the Reliasoft Office DOE software [41].

Checkpoint analysis: A checkpoint analysis was performed to confirm the role of the derived polynomial equation and contour plots in predicting the responses. Values of independent variables were taken at 3 points, 1 from each contour plot, and the theoretical values of PHB Concentration and Compression Force were calculated by substituting the values in the polynomial equation. Mucoadhesive Extended release tablets were prepared experimentally at 3 checkpoints and evaluated for the responses [38-41].

Characterization of PHB base Ibuprofen ER tablet

All Pre-compression characterization PHB blend: The Precompression parameters included Angle of repose, Bulk density, Tapped density, Carr's (Compressibility) index, Hausner's Ratio, of PHB polymer was performed [42,43].

Characterization of ER Ibuprofen tablet using PHB: General appearance, thickness, diameter and volume, tablet hardness, weight variation, uniformity of content and friability [42,43].

The physicochemical evaluation was performed according to European Pharmacopeia (1997).

The tablet thickness is expressed as averages of 5 measurements made at 5 different points between the 2 surfaces of the compact.

Hardness of the tablet of each formulation was determined using Pfizer hardness tester. Three tablets from each formulation batch were tested randomly and the average reading was noted.

Randomly selected 20 tablets were weighed individually and together in a single pan balance. As per Indian Pharmacopeia this method is satisfactory to determine the drug content uniformity. The average weight was noted and standard deviation was calculated.

The test for uniformity of drug content is carried out by collecting a sample of 10 tablets from a batch and determining their individual amount of drugs in each tablet. As per Indian Pharmacopeia this method is satisfactory to determine the average drug content and the content of individual tablets should fall within specified limits in terms of the percentage deviation from the mean.

The test for disintegration time is carried out by Nine hundred millilitres of water maintained at 37°C. DT was determined at the point at which the tablet disintegrated

and passed through the screen of the sinker completely (opening of mesh of the sinker: 3-3.5 mm in height and 3.5-4 mm in width) [27].

The Roche friabilator was used for determination of friability.

Drug content: Ten tablets from each formulation were weighed individually and powdered. The Powder equivalent to 200 mg of Ibuprofen was weighed and dissolved in 10ml of methanol and volume was adjusted to 100 ml with pH 6.8 PBS. From this solution 1 ml was taken and made up to 100 ml using same dilution media, solution was filtered, and analyzed at 222 nm by UV-visible spectrophotometer [44].

Tablet porosity: The tablet porosity was calculated from the dimensions and weight of the tablet and the apparent particle density of the mixture. The apparent density (ρ_{app}) of the compact, were calculated from the ratio of the tablet mass to the volume of the compact [42].

$$(\rho_{app}) \text{ of compacts} = \frac{\text{Mass of tablet}}{\text{Volume of compact}} = \frac{\text{gm}}{\pi r^2 h}$$

The porosity of the compacts was calculated using the relationship

$$\text{Porosity}(\epsilon) = 1 - \frac{\rho_{app} \text{ density of compacts}}{\rho_{true} \text{ density of particles}}$$

Where, ϵ is the porosity of the compacts, ρ_{app} is the apparent density of the compact, and ρ_{true} is the true density of the particles. The ratio of ρ_{app}/ρ_{true} is a measure of the relative density or the solid fraction of the compact.

Tablet tensile strength: A diametric compression test was performed according to test was performed according to European Pharmacopoeia (Resistance to crushing of tablet; n=35) [43]. The tablet crushing load, which is the force required to break flat faced tablet into halves by compression in the radial direction, was measured using a tablet hardness tester. Tensile strength for crushing (T_s) was calculated using the following equation:

$$T_s = \frac{2F}{\pi \cdot dt}$$

Where, F is the crushing load, and d and t denote the diameter and thickness of the tablet, respectively.

In vitro dissolution test: The *in vitro* release rate studies of ER tablet formulation were carried out in USP dissolution test apparatus Type II paddle type (VEEGO, Mumbai) in HCl buffer solution (pH 1.2 \pm 0.1) from 0 to 2 h and potassium phosphate buffer (pH 6.8 \pm 0.1) from 2 to 12 h. Rotation speed of 50 rpm at temperature of 37 \pm 0.5°C and dissolution medium of 900 ml was maintained throughout the experiment. At predetermined time intervals, 5 ml of sample was withdrawn and replaced with the same volume pre-warmed (37 \pm 0.5°C) fresh dissolution medium. The samples withdrawn were filtered through Whatman No. 1 filter paper, and drug content in each sample was analyzed

after suitable dilution using UV/Vis spectrophotometer (UV 1800, Shimadzu) at two different wavelengths, 220 nm for samples in HCl buffer solution pH 1.2 and 222 nm for samples in potassium phosphate buffer pH 6.8 [44]. Cumulative percentage of drug release was calculated using an equation obtained from a standard curve [45,46].

Drug release kinetics (Model dependent approaches):

Model dependent methods are based on different mathematical functions, which describe the dissolution profile. Once a suitable function has been selected, the dissolution profiles are evaluated depending on the derived model parameters. In order to determine the suitable drug release kinetic model describing the dissolution profile [47,48]. The release data obtained were treated according to zero-order (cumulative amount of drug release versus time), Higuchi (cumulative percentage of drug release versus square root of time), Korsmeyer-Peppas (log cumulative percentage of drug release versus log time) Weibull model (log time versus log percent drug release) equation models. Different kinetic models were applied to interpret the drug release kinetics from ER matrix system [49].

Result and Discussion

Biosynthesis of PHB

Screening and characterization of Biopolymer from microbial source: Soil samples were collected near from Biotechnology department TKIET campus, Warananagar. It was found to be loamy and blackish in colour. Isolation and purification of bacterial strains from soil sample was carried out [23]. It were reported that 19 different viable colonies are produced on Nutrient agar plate with time span of 24 hours at 30°C.

Screening for PHB producing bacterial strains: It was found that, out of 19 isolated colonies, 6 showed morphologically distinct characteristics were flooded with Sudan black-B solution. The obtained cell mass from plates was then confirmed by Nile blue staining technique and Volutin Granule staining method. These both staining technique showed positive feedback for intra-granular PHB production.

Harvesting of cellular biomass: shows the dry weight of biomass per 100 ml of nutrient media of the soil isolate and the standard organism *Bacillus megaterium* obtained from agar and broth medium. The all bacterial strains were capable of PHB synthesis. Bacteria accumulate maximum PHB during the stationary phase, in nutrient broth medium PHB yield become limited as compare to stationary phase due to nutrients availability becomes critical after some time period that reason was took into account and nutrient agar medium was selected for further studies. The lowest amounts of biomass showed by soil isolate SS2 that was 36 mg and 21 mg in nutrient agar and nutrient broth respectively [24]. Soil isolate SS5 showed 136 mg and 88 mg in nutrient agar and nutrient broth respectively (Table

Table 1. Dry weight of obtained cellular biomass

Isolate Code	Dry weight of biomass per 100 mL media (mg)	
	Agar	Broth
SS1	119	73
SS2	36	21
SS3	52	23
SS4	187	93
SS5	136	88
SS6	88	45
BM	253	148

BM : *Bacillus megaterium*

Table 1. Dry weight of obtained cellular biomass

Isolate	PHB yield/ dry cell weight (% w/w)	Isolate	PHB yield/ dry cell weight (% w/w)
SS1	12	BM1	22
SS2	9	BM2	28
SS3	11	BM3	36
SS4	6	BM4	27
SS5	15	BM5	32
SS6	14	BM6	41
BM	18		

1). By considered other view of production standard PHB producer *Bacillus megaterium* yields 250 mg of biomass which was greater than biomass yielded by other soil isolates organism hence that standard organism was selected for further production.

Extraction of PHB: Nutrient agar was selected as the medium for maximum PHB yield. When all the bacterial isolates were grown on nutrient agar medium they produced various amount of PHB yield. The isolate SS4 was yielded least amount of PHB yield 6% w/w dry cell weight while, at the same time other isolates SS1, SS2, SS3, SS5, SS6, yielded 12, 9, 11, 15, 14% w/w of dry cell weight respectively (Table 2). On other hand selected standard bacterial producer *Bacillus megaterium* yielded 18% w/w of dry cell weight.

The specific media for *Bacillus megaterium* required for optimum production of PHB were attained from literature. From Table 2 it was found that standard *Bacillus megaterium* strains grown on BM specific medium they produced various extent of PHB yield. The least PHB yield showed by BM1 that was found to be 22% w/w dry cell weight which consisted 1.5% of glucose and 0.1% of peptone concentration. While maximum PHB yield showed by BM3 that was found to be 36% w/w dry cell weight at 3.5% glucose and 0.3% of peptone in media composition contained commercial carbon and nitrogen Source. At same time PHB yield produced by media composition contained cheaply available carbon and nitrogen source. The yield of BM6 was found to be 27% w/w dry cell weight obtained from media containing 1.5% of molasses and 0.1% of ammonium chloride that was least yield, while 41% w/w dry cell weight of maximum

yield obtained from BM6 that was found to be maximum yield as compare to yield obtained from all other media compositions. So BM6 was selected as potential PHB producer on large scale production [21].

Drug Interactions with PHB

Infra-red spectral analysis: Drug -excipients compatibility parameter took into account because it was directly affect the formulations stability and its potential effect on pharmacologic properties of drug candidate on living system. Drug-excipients compatibility confirmed by FT-IR spectroscopy is illustrated in Figure 1. Ibuprofen and physical mixture consisted polymer were took into account. The spectrum was recorded of Ibuprofen at 1419 cm^{-1} , 1230 cm^{-1} , 1380 cm^{-1} , 1702 cm^{-1} , 1321 cm^{-1} and 3090 cm^{-1} . Ibuprofen shows peak at 1419 cm^{-1} corresponds to C-H stretch of the alkenes compound present in the structure. The same peak was aroused in the physical mixture at 1419 cm^{-1} . The peak at 1230 cm^{-1} corresponds to C-C(O)C group represents the esters of acetate compound in ibuprofen; same peak for esters of acetate compound showed by physical mixture at 1230 cm^{-1} . C-N stretch was showed at 1321 cm^{-1} in the ibuprofen while at the same position, physical mixture aroused same stretch in the structure. PHB yields the C-H stretching at position 2982 cm^{-1} the same peak aroused at 2982 cm^{-1} so these peak assignments proved that there were no possible interactions between drug, polymer and drug and polymer excipient physical mixture (Figure 1) [25,26].

Differential Scanning calorimetry: DSC thermogram of physical mixture of drug showed sharp endothermic peak at 77.77°C that analogous to the melting point temperature of ibuprofen (77.25°C). Physical mixture of all above ingredient their identical peaks at defined temperature range. Presence of all peaks indicates that all ingredients are compatible with drug substance means there were no incompatibility between selected ingredients for formulation (Figure 2) [28].

PHB based extended release Ibuprofen tablet

The ER tablet consists of the most obvious factor that showed impact on drug dissolution rate and bioavailability of less aqueous soluble drug candidate. Therefore, three key factors for successful tableting are flow and compactability of the compression mix, and drug content uniformity in the mix and the final tablets. All of these factors are likely to be maintained for better formulation aspect [30,31]. Therefore, formulation strategy took into account and it had become duty to selection of an ideal component for better tableting process. Imminent particle size of preformulated material had also help to minimize segregation of the finely milled drug from the compression mix. It had been observed excipients with a rough surface can interact more strongly with drug particles than a smooth surface excipient [32,33]. Good flow and compaction of the compression mix are largely conferred by the excipients and the primary concern was




Figure 1. FTIR spectra of PHB, Ibuprofen and Physical mixture




Figure 2. Differential scanning calorimetry (DSC) thermogram of physical mixture containing Ibuprofen and PHB

Table 3. Precompression Characterization of PHB based powder Blend

Formulation Code	Angle of repose (θ)	Bulk Density (gm/mL)	Tapped Density (gm/mL)	Carr's Index (%)	Hausner's Ratio
F-1	30.02 ± 0.13	0.52 ± 0.01	0.57 ± 0.02	8.7 ± 0.038	1.10
F-2	32.46 ± 0.34	0.64 ± 0.01	0.72 ± 0.01	11.1 ± 0.092	1.14
F-3	29.63 ± 0.47	0.62 ± 0.01	0.74 ± 0.01	16.5 ± 0.012	1.00
F-4	22.14 ± 0.58	0.59 ± 0.01	0.72 ± 0.02	18.4 ± 0.086	1.23
F-5	27.54 ± 0.88	0.56 ± 0.03	0.63 ± 0.01	11.6 ± 0.036	1.12
F-6	30.51 ± 0.16	0.67 ± 0.01	0.73 ± 0.02	8.06 ± 0.019	1.09
F-7	31.44 ± 0.56	0.53 ± 0.04	0.64 ± 0.03	17.7 ± 0.082	1.21
F-8	32.88 ± 0.99	0.70 ± 0.01	0.78 ± 0.01	10.8 ± 0.090	1.11
F-9	26.56 ± 0.02	0.72 ± 0.01	0.76 ± 0.03	7.3 ± 0.082	1.07
F-10	33.48 ± 0.27	0.65 ± 0.03	0.88 ± 0.01	26.4 ± 0.044	1.34
F-11	29.23 ± 0.13	0.72 ± 0.02	0.81 ± 0.01	11.3 ± 0.021	1.13
F-12	34.62 ± 0.33	0.63 ± 0.03	0.77 ± 0.02	18.1 ± 0.045	1.21
F-13	27.77 ± 0.96	0.56 ± 0.01	0.63 ± 0.01	11.3 ± 0.043	1.13

likely to be achievement of good content uniformity in the blend and in the tablets formulation.

In direct compression technique the finely milled filler binders have been used to exhibit sufficient flow for direct compression and a glidant had used in powder blend to reduce interference with flow. Colloidal silicon dioxide added that improved the flow characteristics of a compression mix [33].

Pre- Compressional Behavior of PHB: Selections of appropriate premixed material were the key of direct compression. Therefore, specially designed Lactose monohydrate (Lactopress®) was selected as filler in the formulation that had comprised of benefitted quality like unique particle size less than 100 μm that added functionality improved flow ability with compactability properties in the formulation. Lactose is mostly used filler in vast range of tablet formulation which enabled with formulation compatibility and universal stability of the product. Screened PHB was added in the formulation as release retardant polymer which exhibited prolonged drug release [34]. All the used material was free flowing, tablet were obtained of uniform weight variation as per pharmacopoeia specifications. Bulk density was found to be between 0.52 ± 0.01 to 0.72 ± 0.02 gm/mL and tapped density was found to be between 0.72 ± 0.02 to 0.88 ± 0.01 gm/mL for all formulations (). From obtained density data % compressibility was calculated and that was found to be between 5.8 ± 0.082 to 26.4 ± 0.044 percent. Angle of repose was found to be in the range of 22.14 ± 0.58 to 34.62 ± 0.33 (Table 3).

A standard value stand for Hausner's ratio less than 1.20 is indication of good flow ability of material, whereas value of 1.5 or higher represents the poor flow ability of material. Exceptionally few formulations cross the limit value of Hausner's ratio. The Carr's index is also known as compressibility index. A values stands between 5 and 15, 12 and 16, 18 and 21 and 23 and 28 indicates excellent, good, fair, and poor flow properties of the material respectively (Table 3).

Table 4. Flow characterization of PHB based powder Blend

Formulation Code	a	b
F-1	0.305	0.037
F-2	0.279	0.040
F-3	0.256	0.048
F-4	0.282	0.043
F-5	0.256	0.048
F-6	0.292	0.035
F-7	0.243	0.048
F-8	0.292	0.038
F-9	0.279	0.040
F-10	0.264	0.051
F-11	0.281	0.036
F-12	0.305	0.039
F-13	0.317	0.041

Kawakita plot: The compaction properties of pharmaceutical powders are characterized by their compressibility and compactability. While compressibility is the ability of the powder to deform under pressure, compactability is the ability to form mechanically to strong compacts. Compaction as applicable to pharmaceutical powder consists of the simultaneous process of compression and consolidation of two phase (particulate solid gas) system due to an applied force [35,36]. 'a' is properties of consolidation as close packing and 'b' is packing velocity. The constant 'a' is equal to the minimum porosity of the bed prior to compression while 'b' which is termed as the coefficient of compression, is related to the plasticity of the material (Table 4). Greater the value of 'b' indicate good compactability, and if packing velocity is high means yield pressure are breaking strength is less. All the formulations indicate the good flow ability but at the same time it shows the poor compactability. The Kawakita elucidating the flow of powder blend shown in Table 4.

Design of experiment

The implementation of Design of Experiments (DoE) optimization techniques invariably encompasses use of experimental designs and generation of mathematical

equations and graphic outcomes, thus depicting an inclusive picture of variation of the product/process response (s) as a function of input variable.

Response surface methodology (RSM) is a rapid technique used to empirically derive a functional relationship between an experimental response and a set of input variables in the development and optimization of drug delivery systems. RSM trim down the number of experimental runs that are necessary to establish a mathematical trend in the experimental design region allow to determine the optimum level of experimental factors required for a given response [37-40].

Central composite design: Central composite design is very efficient and flexible, providing much information on experiment variable effects and overall percentage error in a minimal number of experimental runs. Based on the principles of design of experiments (DoE), the methodology involves the use of various types of experimental designs, generation of polynomial mathematical relationships and mapping of the response over the experimental domain to select the optimum formulation. Therefore, central composite design was found to be a very suitable tool for process optimization of pharmaceutical formulations [38-41]. Systematic optimization procedures are carried out by selecting an objective function, finding the most important or contributing factors and investigating the relationship between responses and factors by the so called response surface methodology.

Optimization data analysis: A central composite statistical design with 2 factors, 3 levels and 13 run was selected to study the effects on dependent variables. All the batches of prepared powder blend were within the experimental design yielded tablets and these tablets were evaluated for hardness, cumulative percent drug

release. The Central composite design gained popularity due to fewer experiment (13 runs) wants to perform. Transformed values all the batches shown in. The all selected dependent variable obtained at various levels of 2 independent variables (X1 and X2) were subjected to multiple regression to yield second order polynomial equation.

$$Y_1 = 95.51 - 1.65 X_1 - 0.94 X_2 - 0.52 X_1 X_2 + 2.72 X_1^2 + 0.89 X_2^2 - 1.476 X_1 X_2^2 - 2.57 X_1^2 X_2$$

$$Y_2 = 4.52 + 1.42 X_1 + 0.18 X_2 + 0.17 X_1 X_2 + 2.02 X_1^2 + 0.033 X_2^2 + 0.04 X_1 X_2^2 + 0.36 X_1^2 X_2$$

Effect of Formulation variables: The range of formulation component with constraints was applied to check the effects of formulation variables on responses. Cumulative drug release (%) and hardness (Kg/cm²) parameter were selected to get desired goal of effective formulation. Formulation variables had impact on responses showed by wide range value obtained from coefficient of term polynomial equations.

Cumulative percent drug release (Y1) strongly affected by employed formulation variable. The main effect of X1 and X2 represents the result of changing the proportion of variable from its low level to high level. The interaction terms (X₁X₂, X₂², X₁X₂², and X₁²X₂) shows how the cumulative percent drug release changes when remained variables are simultaneously changed. The negative coefficients for independent variable indicate an unfavorable effect on drug release. The positive coefficients for the interaction between two variables indicate favorable on drug release. Among the two independent variables the lowest coefficient value is found for X2, indicating that this variable is insignificant in prediction of hardness.




Figure 3. Normal probability plot for effect of cumulative drug release (%) on Poly(3-hydroxybutyrate) base ibuprofen ER tablet

Y1 and Y2 values measured for the different batches showed wide variation of values ranged from 88.99 to 98.29% for Y1 (Figures 3-6 and Figure 8) and 2.56 to 7.57 kg/cm² for Y2 (Figures 9-11 and Figure 13), which is clearly indicate that that Y1 and Y2 value strongly affected by the variables preferred for the optimization study (Tables 5 and 6). The variables also showed impact on other formulation parameters. The main effect produced by X1 and X2 variables represents the average result of

changing one variable at a time from its low level to high level. The negative sign in polynomial equation indicate negative effect on response while positive sign indicate positive effect. The statistical analysis of full model (Tables 7 and 8) shows that the independent variables had a significant effect on the responses.

The standardized effect of the selected factors and their interaction on the responses was investigated by preparing a Pareto charts (Figures 7 and 12), which depicts the main




Figure 4. Probability plot for residual of cumulative drug release (%) on Poly(3-hydroxybutyrate) base ibuprofen ER tablet




Figure 5. Plot for residual versus fitted value of cumulative drug release (%) on Poly (3-hydroxybutyrate) base ibuprofen ER tablet




Figure 6. Fitted versus actual values of cumulative drug release (%) on Poly (3-hydroxybutyrate) base ibuprofen ER tablet




Figure 7. Pareto chart showing the standardized effect of independent variables and their interaction on cumulative drug release (%) on Poly (3-hydroxybutyrate) base ER tablet

effect of the independent variables and interactions which their relative significance on the Y1 and Y2. The length of each bar indicates the standardized effect of that factor in the responses. Factors remains inside the reference line indicate that these terms contribute the least in prediction of responses.

To graphically evaluate, the data with the help of standardized Pareto charts (Figures 7 and 12). These charts consist of bars, lengths of which are proportional to the absolute value of the estimated effect, divided by the standard error. The charts include vertical line at the critical

P value of 0.05. An effect that exceeds the vertical line is considered to be statistically significant. Figure 7 Indicates that polymer concentration (X1) and compression force (X2) were the factors which represents the individual effect on the responses. The interaction effect shows the impact of polymer concentration and compression force on particular response. The interaction matrix predicts the 50 mg polymer at 0.37 ton applied pressure yields the 95.51% of drug release with 4.52 Kg/cm² hardness (Figure 12).

ANOVA, pure error and Lack of fit: For estimation of




Figure 8. Interaction matrix of concentration of dependent variable on cumulative drug release (%) on Poly (3-hydroxybutyrate) base ibuprofen ER tablet




Figure 9. Normal probability plot for effect of hardness (Kg/cm²) on Poly (3-hydroxybutyrate) base ibuprofen ER tablet

coefficients in the approximating polynomial function applying uncoded values of factor levels, the multiple regression analysis (MLRA) method was followed.

For estimation of significance of the model, the analysis of variance (ANOVA) was applied. Using 5% significance level, a model is considered significant if the P-value (significance

probability value) is less than 0.05 (Tables 7 and 8) [41]. It can be concluded that for all two responses, the interaction effect (cross product contribution) of the model was not significant for both response Y1 and Y2, only linear contribution of the model was significant, whereas for responses Y1, and Y2 and quadratic contribution of the model was not significant for both responses. Calculating the Pearson correlation




Figure 10. Probability plot for residual of hardness (Kg/cm²) on Poly(3-hydroxybutyrate) base ibuprofen ER tablet




Figure 11. Plot for residual versus fitted value of hardness (Kg/cm²) on Poly (3-hydroxybutyrate) base ibuprofen ER tablet

coefficients (R^2), it was found that 66.29 and 89.44 for Y1 and Y2 respectively of the variability of experimental data could be explained using the model polynomial functions. Therefore, it can be concluded that model functions Y1 and Y2 well interpreted the variability of data after 12 h of drug release the model polynomial function is found to be less adequate (Tables 7 and 8).

The data of pure error and lack of fit are depicted in (Tables 7 and 8). These can provide a mean response and an estimate of pure experimental certainty. The residual are the difference between observed and predicted value. The effects like, the polymer concentration of PHB used it had varying degree of impact at different compression force. Hence the




Figure 12. Pareto chart showing the standardized effect of independent variables and their interaction on hardness (Kg/cm²) on Poly (3-hydroxybutyrate) base ER tablet




Figure 13. Interaction matrix of concentration of dependent variable on hardness (Kg/cm²) on Poly (3-hydroxybutyrate) base ibuprofen ER tablet

above results leads the response parameters conforms at optimal PHB concentration and midpoint of the drug release profile and hardness of ER Tablet compression force.

The residual represents difference between the observed and predicted values, given that computed F values were respectively lower than critical values, which denotes non significance with regard lack of fit (Tables 7 and 8). To confirm the error of non-significant term, F statistic was calculated after applying analysis of variance for the full model. To access the pure error of the experiments and enabled the model's lack of fit to be checked. In this study, the model was checked for lack of fit for all the responses. For lack of fit P value obtained 0.0062 and 0.0015 for Y1 and Y2 respectively (Tables 7 and 8). Hence the current model provided a satisfactory fit to the data and had no lack off fit.

Counter plots and response surface analysis: The graphical outcome is convenient way to understand any conceptual task as compare to data expressed by text manner. So the software generated response two-dimensional (2D) counter plots and three-dimensional (3D) surface plots (Figures 14 to 17) was very useful to predict the responses obtained from experimental work done. These plots are useful to understand the relationship between the dependent and independent variables, also helpful to understand the effect of two factors one response at the same time. Three-dimensional (3D) plots for the measured responses were formed, based on the model polynomial functions to assess the change of the response surface. Since the model has two factors, both factors were held constant for each response. The effect

of PHB concentration (X1) and compression force (X2) with their interaction on cumulative percent drug release % (Y1) explaining that the varying degree of drug release attained at changing the proportion of polymer concentration (Figures 14 and 15). About 92.13%, 94.52%, 96.90% drug release attained at near about 58 mg, 54 mg, 42 mg, of employed PHB concentration and 470, 420, 360 tons of applied compression force respectively (Figure 14). The prediction of hardness both factors were held constant while 6.25, 4.58, 3.58 kg/cm² hardness at 58, 50, 42 mg polymer concentration and 455, 375, 380 tons of compression force respectively (Figures 16 and 17 and Table 6). These responses concluded that as per polymer concentration and compression force increases drug release decreases and hardness increases.

Checkpoint analysis: By following the main and interaction effects on the gained response values, the central composite design is found be useful in obtaining the optimal solution in which the levels of X₁ and X₂ were predefined (Figure 18) [41]. In this case optimized formula was theoretically obtained to yield cumulative drug release (%) and hardness (kg/cm²).

As confirmation of this process software suggested batch was took into account and formulation was prepared at the optimum levels of independent variables and evaluated. The observed value of responses Y₁ and Y₂ (Table 9) had given a close agreement with the predicted values.




Figure 14. Counter plot showing effect of PHB concentration and compression force on cumulative drug release (%) (Y1) of Poly (3-hydroxybutyrate) base ibuprofen ER tablet




Figure 15. Counter plot showing effect of PHB concentration and compression force on hardness (Y2) of Poly (3-hydroxybutyrate) base ibuprofen ER tablet




Figure 16. Response surface 3D plot showing effect of PHB concentration and compression force on cumulative drug release (%) (Y1) of Poly (3-hydroxybutyrate) base ER tablet

Software suggested batch was prepared and evaluated for cumulative drug release (%) and hardness (Kg/cm²) (Table 9), indicate that the measured cumulative percent release (%) and hardness values were as expected. When cumulative percent drug release values were compared with predicted cumulative drug release (%) values found

to be insignificant. Thus we conclude that the obtained mathematical equation is valid for predicting the hardness.

Characterization of poly (3-Hydroxybutyrate) base Ibuprofen ER tablet

Poly-(3-hydroxybutyrate) base ibuprofen ER tablet

Table 5. Central composite experimental design for preparation of Poly(3-hydroxybutyrate) base ibuprofen ER tablet

Run order/ Batch N0	Independent variable			
	PHB concentration (Mg) (X1)	Compression Force (Tons) (X2)		
1	-1		1	
2	0		-1.41	
3	0		0	
4	-1.41		0	
5	0		0	
6	0		0	
7	0		1.41	
8	0		0	
9	1		-1	
10	1.41		0	
11	1		1	
12	0		0	
13	-1		-1	
Independent variables		Low	Medium	High
A=Concentration of PHB (mg)		40	50	60
B=Compression Force (Tons)		0.25	0.375	0.5
Dependent variables (Responses)				
Y1=Cumulative drug release (%)				
Y2=Hardness (Kg/cm ²)				

Table 6. Central composite experimental design two variables and their experimental and predicted response for cumulative drug release (%) and Hardness (Kg/cm²)

Run order	Cumulative drug release (%)			Hardness (Kg/cm ²)		
	Actual Value	Fitted Values	Residual	Actual Value	Fitted Values	Residual
1	95.21	95.89	-0.68	3.25	3.39	-0.14
2	95.07	94.55	0.52	4.37	4.51	-0.14
3	95.96	95.51	0.45	4.44	4.52	-0.08
4	98.29	98.45	-0.15	2.56	2.82	-0.26
5	94.91	95.51	-0.60	4.49	4.52	-0.03
6	95.87	95.51	0.36	4.73	4.52	0.21
7	93.68	91.87	1.80	5.63	5.03	0.59
8	95.88	95.51	0.37	4.49	4.52	-0.03
9	92.83	94.48	-1.64	5.56	5.87	-0.31
10	96.27	93.78	2.48	7.57	6.85	0.71
11	88.99	91.54	-2.55	5.75	6.58	-0.83
12	94.91	95.51	-0.60	4.45	4.52	-0.07
13	96.95	96.73	0.22	3.76	3.37	0.38

were prepared using central composite design. The post compression characterization of formulated tablets (Table 10) and other formulation parameters were found to be good for different formulated batches. The drug content was found to be uniform for all formulations and ranged from 96.26 to 99.77%. Results also showed conceded and reliable distribution of drug in tablets. The formulated tablets were also evaluated for thickness and weight of formulated tablets that were ranged from 3.90 to 4.68 mm, and 596 to 601 mg respectively. All the formulated tablets followed the USP standards for weight variation of the each single unit of the formulation [42,43]. The hardness alias crushing strength is the prime parameter of tablet the formulation, which withstand mechanical strength during formulation handling and transportation, hardness

of the formulated tablet should took into account during in process formulation development. Another foremost parameter is friability; the effected tablet formulations were attained friability of most of batches were below 1%, indicating that the friability for all the formulations within the compendia limits (USP 31) and had a good mechanical strength.

Tablet tensile strength: The compactability of pharmaceutical powders can be characterized by studying tensile strength. Tensile strength and indentation hardness to determine three dimensionless parameters strain index, bonding index, and brittle fracture index-to characterize tableting performance of individual components and mixtures [42,43]. Values of tensile strength calculated

Table 7. Analysis of Variance (ANOVA) of cumulative drug release (%)

Source of Variation	Degree of Freedom	Sum of Squares [Partial]	Mean Squares [Partial]	F Ratio	P Value	
Model	5	40.71	8.142	2.75	0.1	
Linear Effect	2	28.96	14.48	4.89	0.04	
Interaction Effects	1	1.11	1.11	0.37	0.55	
Quadratic Effects	2	10.63	5.31	1.79	0.23	
Residual	7	20.7	2.95	-	-	
Lack of fit	3	19.49	6.49	21.56	0.0062	
Pure Error	4	1.2	0.3	-	-	
Total	12	61.41	-	-	-	
R-sq=66.29%		R-sq(pred)=0%				
R-sq(adj)=42.21%						
Regression Information						
Term	Coefficient	Standard Error	Low CI	High CI	T-Value	P-Value
Intercept	95.51	0.76	94.05	96.96	124.18	5.79
PC: Polymer Con.	-1.65	0.6	-2.8	-0.49	-2.71	0.03
CF: Compression Force	-0.94	0.6	-2.09	0.2	-1.55	0.16
PC • CF	-0.52	0.85	-2.15	1.1	-0.61	0.55
PC • PC	0.3	0.65	-0.93	1.53	0.46	0.65
CF • CF	-1.14	0.65	-2.38	0.08	-1.76	0.12

Table 8. Checkpoint Analysis of Poly (3-hydroxybutyrate) base ibuprofen ER tablet after CCD experimental design

Source of Variation	Degree of Freedom	Sum of Squares [Partial]	Mean Squares [Partial]	F Ratio	P Value	
Model	5	16.84	3.36	2.75	0.0026	
Linear Effect	2	16.47	8.23	4.89	0.0004	
Interaction Effects	1	0.12	0.12	0.37	0.5324	
Quadratic Effects	2	0.25	0.12	1.79	0.6542	
Residual	7	1.98	0.28			
Lack of fit	3	1.93	0.64	21.56	0.0015	
Pure Error	4	0.0572	0.01			
Total	12	18.83				
R-sq=89.4432%		R-sq(pred)=26.61%				
Rsq(adj)=81.90%						
Regression Information						
Term	Coefficient	Standard Error	Low CI	High CI	T Value	P Value
Intercept	4.52	0.23	4.06	4.97	18.96	2.82
PC: Polymer Con.	1.42	0.18	1.06	1.78	7.55	0.0001
CF: Compression Force	0.18	0.18	-0.17	0.53	0.96	0.36
PC • CF	0.17	0.26	-0.32	0.67	0.65	0.53
PC • PC	0.15	0.20	-0.22	0.54	0.78	0.45
CF • CF	0.12	0.20	-0.25	0.50	0.62	0.55

Table 9. Demographic data and GAGS and AQoL values at T0, expressed per gender

Independent variables		Cumulative drug release (%)		Hardness (Kg/cm ²)	
A	B	Measured	Predicted	Measured	Predicted
0	0	95.19 ± 0.91	95.51	4.46 ± 0.37	4.52


from the forces required radially and axially are called respectively, radial and axial tensile strengths. This is important parameter affects tablet's strength and interrelation between powder particles and interparticulate

binding force, such as the surface molecular interaction and mechanical interlocking (Table 10). Tensile strength of ordered batches was found to be range between 0.029 ± 0.001 to 0.094 ± 0.002.

Table 10. Physical Characterization of Poly (3-hydroxybutyrate) base ibuprofen ER tablet after CCD experimental design

Formulation Code	Thickness (mm)	Hardness (Kg/cm ²)	Friability (%)	Weight Variation (Mg)	Drug Content (%)	Tensile Strength
F-1	4.68 ± 0.03	3.25 ± 0.08	0.86 ± 0.03	599.20 ± 0.05	97.25 ± 0.34	0.033 ± 0.001
F-2	4.57 ± 0.13	4.37 ± 0.25	0.66 ± 0.03	598.08 ± 0.14	99.77 ± 0.28	0.045 ± 0.002
F-3	4.55 ± 0.04	4.44 ± 0.35	0.64 ± 0.04	599.14 ± 0.02	98.25 ± 0.37	0.050 ± 0.001
F-4	4.41 ± 0.07	2.56 ± 0.11	1.23 ± 0.02	596.40 ± 0.23	99.44 ± 0.28	0.029 ± 0.001
F-5	4.47 ± 0.03	4.49 ± 0.14	0.63 ± 0.04	600.04 ± 0.58	97.47 ± 0.38	0.051 ± 0.002
F-6	4.63 ± 0.02	4.73 ± 0.31	0.66 ± 0.04	599.12 ± 0.10	96.26 ± 0.17	0.052 ± 0.002
F-7	4.32 ± 0.02	5.63 ± 0.37	0.63 ± 0.04	600.91 ± 0.06	99.26 ± 0.47	0.064 ± 0.001
F-8	4.45 ± 0.04	4.49 ± 0.14	0.61 ± 0.03	598.51 ± 0.59	99.06 ± 0.43	0.051 ± 0.002
F-9	4.32 ± 0.06	5.56 ± 0.29	0.58 ± 0.02	600.63 ± 0.22	97.49 ± 0.40	0.063 ± 0.001
F-10	3.97 ± 0.02	7.57 ± 0.40	0.49 ± 0.03	599.32 ± 0.17	98.54 ± 0.25	0.094 ± 0.002
F-11	4.50 ± 0.05	5.75 ± 0.15	0.57 ± 0.02	600.34 ± 0.11	99.24 ± 0.26	0.064 ± 0.002
F-12	4.62 ± 0.06	4.45 ± 0.29	0.66 ± 0.03	599.82 ± 0.16	96.81 ± 0.37	0.063 ± 0.001
F-13	3.90 ± 0.04	3.76 ± 0.27	0.87 ± 0.03	601.88 ± 0.61	99.43 ± 0.20	0.047 ± 0.002

n=3 ± SD

Figure 17. Response surface 3D plot showing effect of PHB concentration and compression force on hardness (Y₂) of Poly (3-hydroxybutyrate) base ibuprofen ER tablet

In vitro dissolution study: The *in vitro* dissolution testing was conventionally known as a tool for ensuring batch-to-batch consistency. It is also an essential mean for deciding on a candidate formulation in product development [45]. The tests should be sensitive enough to demonstrate any small variable in manufacturing of a product as well as the type and level of excipients used. Therefore, it is possible that an over-discriminatory test, although *in vivo* irrelevance might be suitable for these purposes [46].

The amount of Ibuprofen released as function of time was measured by *in vitro* dissolution study. The *in vitro* dissolution studies were carried out in desired simulated condition to obtain consistent drug release over prolonged

period of time from ER formulation. The cumulative drug release attained by ordered ER formulation batches at initial five hours not more than 25%, after the 9 h drug release reached up to 60% leads to speedy erosion of surface of tablet due to saturation of exterior environ of tablet (Figure 19). At 12 hour cumulative drug release reached for all the formulations ranging from 88.99 to 99.29%. The core aspect of prolonged drug release from ER tablet was incorporation of synthesized biopolymer (PHB) as release retardant tool. This polymer when come in contact with phosphate buffer solution at specified simulated *in vitro* conditions it get hydrated and forms a gel. The drug release from this gel will be usually diffusion controlled and hence the release will be extended




Figure 18. Effect of change in concentration of dependent variables and optimal responses on Poly (3-hydroxybutyrate) base ibuprofen ER tablet

over a prolonged period of time. Drug release of Ibuprofen from diffusion membrane did not significant impact on employed compression force during tableting process. But the polymer substance entangled with formulation components and reduced interparticulate space lead to stiffed arrangement and drug release was retarded. The cumulative drug release of Ibuprofen from most of formulations concluded that near about 95% drug was dissolved within 12 hours indicates that, drug release was effectively prolonged. The consistent drug release pattern were obtained from ordered ER formulations indicating that resulted dissolution profile met the expected formulations requirement for the extended release product.

Characterization of optimized Poly(3-hydroxybutyrate) base ibuprofen ER tablet: The optimized formulation is key aspect of successful formulation development. The effect of independent variables on the responses, various applied levels used to determine the optimum responses. The optimum formulation is that gives the maximum drug release and at the same time high value of hardness with input of low amount of process variable i.e. Polymer concentration and applied compression force [47]. It is evident from polynomial equation and plots increasing amount of polymer concentration increases the hardness and decreases the drug release. So it is clear that, medium level was selected for all independent variables using computer optimization process. Medium showed significant responses so medium level was selected for development of optimized batch [48].

A central composite design was employed to study the effect of formulation variable on cumulative drug release and hardness by application of optimization technique. The obtained results revealed amount of PHB and applied compression force affected significantly the response variables. The values of responses close with predicted values of optimized formulation suggested by software. The pragmatic responses for the optimum formulation were in close concurrence with the predicted values, demonstrating the excellent predictability of the optimization procedure [49].

A statistical model was developed by software remarkably demonstrate the feasibility of optimization technique. Predicted drug release profile of the formulation is helpful in the extended release drug delivery system (ERDDS) to provide consistent drug release for prolonged period of time by minimizing the dosing frequency [50].

The optimized formulation was prepared according to the predicted values and evaluated for variety responses. A good relativity was observed in predicted and experimental values, which conforms practicability and validity of the model.

Comparative study: The effective polymer screening and characterization process was not only emphasizing goal of formulation but also necessary to check the effectiveness of polymer by evaluating the comparable *in vitro* drug release profile with commercial polymer (HPMC).

In comparative drug release profile the same formulation




Figure 19. *In vitro* drug release profile of Poly(3-hydroxybutyrate) base ibuprofen ER tablet

parameters was employed for HPMC with use of same quantity of polymer concentration; and compression force as compare with optimized formula for PHB. The same experimental condition was maintained for dissolution study. Both formulations figure out the varied extent of drug release within 12 hours (Figure 20).

Dissolution study of PHB and HPMC based formulations gave up drug release at third hour up to 12.12 and 15.96%, at sixth hour 32.53 and 51.47% respectively, while at sixth hour PHB and HPMC attained 32.53% and 51.47% of drug release reveals that PHB polymer releases the drug at consistent manner with less than half quantity of drug release while at the same time HPMC release more than half quantity of drug release (Figure 20). At the 09 hour PHB released 59.32% while, HPMC attained 81.56% i.e.

maximum drug release subjected to that declined drug release profile. PHB attained highest cumulative percent drug release 95.33% at 12 hour so it was concluded that the PHB has ability to satisfactorily extend the drug release in comparison with commercial polymer.

Model dependent method to compare dissolution profile: Zero-order rate equation, which describes the systems where the release rate is independent of the concentration of the dissolved species. Weibull introduced a general empirical equation which is highly applied to drug dissolution or release from pharmaceutical dosage forms. The Higuchi square root equation describes the release from systems where the solid drug is dispersed in an insoluble matrix, and the rate of drug release is related to the rate of drug diffusion. The Korsmeyer-Peppas equation is used to analyze the release of pharmaceutical polymeric dosage forms, when the release mechanism is not well known or when more than one type of release phenomena could be involved. The erosion equation describes the drug release from slabs, spheres and infinite cylinders displaying heterogeneous erosion. The applicability of all of these equations was tested on optimized formulation [47-49].

From the obtained R^2 values for model dependent drug release profile found to be 0.969 for zero order, 0.818 for Higuchi model, and 0.881 for Weibull model. Korsmeyer Peppas model is used to study the mechanism of drug and the slope of the plots gives the diffusional exponent 'n'. The value found to be for diffusional exponent was 0.465. The obtained exponent belongs to cylinders geometry with anomalous transport. In this model dependent *in vitro* drug release profiles from optimized formulations could be best expressed by Zero order equation as the plots showed highest linearity ($R^2=0.969$). It can be inferred that the release was dependent on Zero-order release due to the dissolution of polymeric matrix and relaxation of the polymer chain. This finding was also in agreement with obtained results for zero-order and it was elected as best fit model for model dependent drug release kinetics.

Conclusion

The current study was based on screening of biopolymer which would satisfy the growing demand of sustainable economic biopolymer production from bacterial genera. Screened Poly-β-hydroxybutyrate (PHB) has found to be an optimistic role of in biomedical applications and pharmaceutical drug delivery scenario. Polyhydroxybutyrate (PHB) polymer shows good physicochemical assessment of with drug and excipients. There were no drug-excipient/ drug-excipient admixture interaction observed. Satisfactorily Preformulation, Precompression, post compression characteristic parameters observed in PHB based ER release compact. PHB based Ibuprofen oral extended release tablet was successfully extends the ibuprofen release in with comparison with HPMC.




Figure 20. In vitro drug release of Poly (3-hydroxybutyrate) and HPMC base ibuprofen ER tablet

Conflict of Interest

The Authors declare that they have no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

Acknowledgements

The authors gratefully acknowledge the Unique Biologicals, Kolhapur and Tatyasaheb Kore College of Pharmacy, Warananagar in procurement of materials, laboratory permission, analysis and characterization of PHB.

Funding

This research has received grant from Shivaji University, Kolhapur, Maharashtra, India with Grant Number: SU/ C & U. D. Section/ UGK/5/453-5 dated 30 Jul 2016.

References

- Lee S, Choi J, Wong H. Recent advances in polyhydroxyalkanoate production by bacterial fermentation: mini review. *Int J Biol Micromol.* 1999; 25:31-36.
- Findlay RH, White DC. Polymeric Beta-Hydroxyalkanoates from Environmental Samples and *Bacillus megaterium*. *Appl Environ Microbiol.* 1983; 45:71-78.
- Hiraishi A, Khan ST. Application of polyhydroxyalkanoates for denitrification in water and wastewater treatment. *Appl Microbiol Biotechnol.* 2003; 61:103-109.
- Samantaray S, Mallick N. Production and characterization of poly- β -hydroxybutyrate (PHB) polymer from *Aulosira fertilissima*. *J Appl Phycol.* 2012; 24:803-814.
- Steinbüchel A, Schlegel HG. Physiology and molecular genetics of poly(beta-hydroxy-alkanoic acid) synthesis in *Alcaligenes eutrophus*. *Mol Microbiol.* 1991; 5:535-542.
- Hauisman G, Leeuw O, Eggink B. Synthesis of poly-3-hydroxyalkanoates is a common feature of fluorescent pseudomonads. *Appl Environ Microbiol.* 1989; 55:1949-1954.
- Wang F, S Lee. Poly(3-hydroxybutyrate) Production with High Polymer Content by Fed-Batch Culture of *Alcaligenes latus* Under Nitrogen Limitation. *Appl Environ Microbiol.* 1997; 63:3703-3706.
- Lemoigne M. Products of dehydration and of polymerization of P-hydroxybutyric acid. *Bull Soc Chem. Biol.* 1926; 8:770-782.
- Jirage AS, Baravkar VS, Kate VK, Payghan SA, Disouza JI. Poly- β -Hydroxybutyrate: Intriguing Biopolymer in Biomedical Applications and Pharma Formulation Trends. *Int J Pharma Bio Arch.* 2013; 6:1107-1118.
- Ankur S, Vaishali K, Santosh P. Lornoxicam Based Solid Dispersion of Spray-Dried Cellulose Nanofibers as Novel Tablet. *Inventi Rapid: Pharm Tech.* 2016; 4:1-11.
- Omar S, Rayer S, Equaab A, Viss R, Steinbüchel A. Optimization of cell growth and poly- β -hydroxybutyrate accumulation on date syrup by *Bacillus megaterium* strain. *Biotechnol Lett.* 2001; 23:1119-1123.
- Verlinden R, Hill D, Kenward M, Williams C, Radecka I. Bacterial synthesis of biodegradable Polyhydroxyalkanoates. *J Appl Microbiol.* 2007; 6:1437-1449.
- Bonartsev AP, Livshits VA, Makhina TA, Myshkina VL, Bonartseva GA. Controlled release profiles of dipyridamole from biodegradable microspheres on the base of poly (3-hydroxybutyrate). *eXPRESS Polymer Letters.* 2007; 1:797-803.
- Bonartsev AP, Bonartseva GA, Makhina TK, Mashkina VL, Luchinina ES. New poly-(3-hydroxybutyrate)-based systems for controlled release of dipyridamole and indomethacin. *Prikl Biokhim Mikrobiol.* 2006; 42:710-715.
- Yu J, Chen LX. Cost-effective recovery and purification of polyhydroxyalkanoates by selective dissolution of cell mass. *Biotechnol Prog.* 2006; 22:547-553.
- Payghan SA, Kate V. Interactive mixture of piroxicam and polymers for development of mucoadhesive fast disintegrating sublingual tablet: In vitro in vivo evaluation. *J Phar SciTech.* 2015; 5:32-44.

17. Payghan SA, Khade D, Sayyad FJ. Formulation and evaluation of new effervescent tablet of famotidine for peptic ulcer therapy. *Inventi Rapid:Pharm Tech* 2015; 2:1-19.
18. Payghan SA, Kate VK, Khavane K, Purohit SS. Pharmaceutical Solid Polymorphism: Approach in Regulatory Consideration. *J Glob Phar Tech.* 2010; 1:45-53.
19. European Pharmacopoeia 4th Edtn. Suppl. 4.1, Published by the directorate for the quality of medicines of the council of Europe 9EDQM, Strasbourg, France, 2002.
20. Hartman T. The use of Sudan Black B as a bacterial fat stain. *Stain Tech* 1940; 15:23-28.
21. Stokes K, Kimbrough C. Studies of the common aerobic spore-forming Bacilli staining for fat with Sudan Black B-stain. *J Bact.* 1942; 43:717-724.
22. Kunasundari B, Sudesh K. Isolation and recovery of microbial Polyhydroxyalkanoates. *express Polymer Lett.* 2011; 7:620-634.
23. Pandit P, Ghat B, Kulkarni C, Mungi D, Patel T. PHB production using novel agro-industrial sources from different bacillus species. *Int J Pharm Bio Sci.* 2011; 2:3.
24. Chaijamrus S, Udpuay N. Production and Characterization of Polyhydroxybutyrate from Molasses and Corn Steep Liquor produced by *Bacillus megaterium* ATCC 6748. *Agr Eng Int.* 2008; 10:1-9.
25. Kate VK, Payghan SA. Physicochemical Evaluation of mannitol Based mucoadhesive fast disintegrating tablet for rapid absorption of piroxicam. *Inventi Rapid:Pharm Tech.* 2013; 3:1-15.
26. Kate VK, Payghan SA, Shinde AJ. Effect of Aging Conditions on the Dissolution Stability of Piroxicam Mucoadhesive Fast Disintegrating Tablet. *Inventi Rapid:NDDS.* 2013; 2:1-6.
27. Kate VK, Payghan SA. Effect of Bioadhesion and Permeability on Dissolution Behavior of Piroxicam Mucoadhesive Fast Disintegrating Tablet. *Inventi Rapid:Pharm Tech* 2013; 2:1-7.
28. Kadoli P, Payghan SA, Disouza JI. Study of Binding Efficiency of Tapioca Starch using lornoxicam as a model drug. *Int J Pharm Bio Arch.* 2012; 3:566-571.
29. Payghan SA, Kate VK, Purohit S, Bhandari A. Effect of Aging Conditions on the Dissolution and Diffusion Stability of Non Aqueous Emulsion. *Inventi Impact:Pharm Tech* 2012; 3:191-196.
30. Shaikh KN, Payghan SA, Disouza JI. Formulation of Gastroretentive drug delivery system of Nifedipine. *Int J Pharm.* 2011; 2:2929-2933.
31. Shaikh K, Patwekar S, Payghan SA, Disouza JI. Formulation and evaluation of sustained release tablets from solid dispersions of lovastatin. *Pharmaturator.* 2011.
32. Shinde SM, Payghan SA, D'souza JI. Physicochemical assessment of pharmaceutical salt Forms: a quality attribute. *Int Res J Inv Pharm Sci* 2014; 2:46-53.
33. Dube V, Payghan SA, Disouza JI. Development of colon targeted lornoxicam matrix tablet. *Int J Pharm.* 2011; 3:226-232.
34. Payghan SA, Shrivastava DN. Potential of solubility in drug discovery and development. *Pharm.*
35. Musle K, Payghan SA, Disouza JI. Formulation, evaluation & development of bilayer tablet. *Int J Pharm. Res Development* 2011; 3:80-87.
36. Payghan SA, Raut M, Kate VK. Development of Sustained Release Desvenlafaxine Succinate Hydrophobic Matrix System using Melt Granulation Technique. *Liter J Pharm Drug Deliv Tech.* 2015; 1; 14-26.
37. Kate VK, Payghan SA. Development of Directly Compressible Mucoadhesive Fast Disintegrating Sublingual Tablet System of Piroxicam Using 3 factor, 3 Level Box Behnken Design. *Asian J Bio Pharm Sci.* 2013; 3:1-6.
38. Taufik BN, Adhav AJ, Payghan SA. Composition of Terbinafine HCL polymeric gel for mucosal drug delivery. *Int J Bio, Pharm Allied Sci.* 2016; 5:2146-2168.
39. Nalavade PS, Landge KS, Kate VK, Payghan SA. Effect of formulation Variables on physicochemical properties of Cholecalciferol Nonaqueous Nanoemulsion. *Asian J Pharm.* 2016; 10:S357-S372.
40. Payghan SA, Cheke PA, Jirage AS. Bioprofiling and Chemoprofiling of Stevia rebaudiana Potential Natural Sweetener as an Excipient Portfolio. *Inventi Impact:Novel Excipients.* 2014; 4:149-162.
41. Jadhav CM, Kate V, Payghan SA. Investigation of effect of non-ionic surfactant on preparation of griseofulvin non-aqueous nanoemulsion. *J Nanostruct Chem* 2015; 5:107-113.
42. Toppo E, Payghan SA, Bhargava S. Role of bioprofiling and chemo profiling for herbal drugs: A Review. *Int J Green Pharm* 2007; 1:7-10.
43. Patil A, Payghan SA, Disouza JI. Formulation and Evaluation of Enteric coated Tablets of Azithromycin dehydrate. *Int J Chem Tech Research* 2011; 3:1479-1484.
44. Bazzo C, Macedo A, Crenca J, Silva V, Pereira M, Zétola M, Pezzini B. Microspheres prepared with biodegradable PHBV and PLA polymers as prolonged-release system for ibuprofen: in vitro drug release and in vivo evaluation. *Braz J Pharm Sci.* 2012; 48:773-780.
45. Prashant P, Vaishali K, Santosh P. Development and Stability Assessment of Solid Self-micro Emulsifying System for Oral Bioavailability of Ezetimibe using Spray-drying Technique. *Inventi Impact:Pharm Proc Devel.* 2016; 3:135-142.
46. Khayyam S, Patwekar S, Payghan SA, Disouza JI. Dissolution and Stability Enhancement of Poorly Water Soluble Drug – Lovastatin by Preparing Solid Dispersions. *Asian J Biom Pharm Sci* 2011; 14:24-31.
47. Payghan SA, Kate VK, Purohit S, Bhandari A. Goodness of Fit Model Dependent Approach for Release Kinetics and In vitro Release of Piroxicam from PEGS Based Non Aqueous Emulsion. *Inventi Impact:Pharm Tech* 2012; 3:183-190.
48. Patil SC, Payghan SA, Disouza JI. Formulation and Evaluation of Oral Disintegrating Tablet of Lornoxicam. *Int J Pharm Bio Arch.* 2011; 2:1518-1523.
49. Payghan SA, Purohit SS, Shrivastava DN. Non-aqueous emulsion: versatile vehicle for drug delivery. *Pharmaceut Rev.* 2008.

50. Wanga B, Sharma-Shivappa RR, Olsonb JW, Khan SA. Production of Polyhydroxybutyrate (PHB) by *Alcaligenes latus* using sugarbeet juice. *J Ind Crop and Pdt.* 2013; 43:802-811.

***Correspondence to**

Santosh Ambadas Payghan
Department of Pharmaceutics
Tatyasaheb Kore college of Pharmacy
Warananagar, Panhala, Kolhapur-416113, India.
Tel: +919096202858
E mail: sapayghan.tkcp@gmail.com